Guardant Health (GH) announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. “2024 was an outstanding year for Guardant. We delivered key milestones across the portfolio and completed the upgrade of Guardant360 LDT onto our Smart Liquid Biopsy platform. We finished the year strong with preliminary full year revenue growth of 31%, driven by strong clinical and biopharma revenue and increasing Guardant360 ASPs. Looking ahead, we believe we are well positioned to continue to drive growth in our oncology business,” said Helmy Eltoukhy, co-founder and co-CEO.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $45 from $40 at Bernstein
- Guardant Health Shield test selected for use in NCI Vanguard study
- Guardant Health enters partnership with MiBA
- Guardant Health and COTA partner in advanced oncology R&D
- Guardant Health announces collaboration with Boehringer Ingelheim